COREGO: drug-drug interaction analysis on the efficacy and safety of regorafenib in patients with a sarcoma: pooled analysis of the data from the REGOSARC and REGOBONE trials.

ABSTRACT:

Background

Regorafenib, an antiangiogenic multikinase inhibitor (MKI), showed antitumour activity in the second line of treatment for sarcomas in the phase II, randomised versus placebo, multicentre clinical trials REGOSARC (NCT01900743) and REGOBONE (NCT02389244). MKIs are drugs with a narrow therapeutic index subject to drug-drug interactions. The co-medications were not included in the trials' analyses.

Materials and methods

We conducted an ancillary exploratory analysis of the two trials to evaluate the interactions between regorafenib and patients' co-medications administered at baseline in terms of efficacy [progression-free survival (PFS)] and toxicity. The efficacy analysis was stratified according to histology groups.

Results

Overall, 289 patients were includ

SUBMITTER: Rethouze F 

PROVIDER: S-EPMC12152544 | biostudies-literature | 2025 Jun

REPOSITORIES: biostudies-literature